natgillin/translations-raw huggingface dataset:
Til kardiovaskulære patienter i stabil tilstand skal benefit/risk-forholdet løbende vurderes for hver enkelt patient, idet der tages højde for fordelene ved at sænke uratniveauet i forhold til en potentielt øget kardiel risiko (se pkt. 
For cardiovascular patients in a stable condition, the benefit/risk balance should be assessed for each individual patient on an ongoing basis, taking into account the benefits of lowering urate levels versus a potential increase in cardiac risk (see section 4.8).
Disse serumkreatininstigninger forsvandt generelt af sig selv og for de flestes vedkommende uden behandlingsafbrydelse. 
These serum creatinine elevations generally resolved, most without treatment interruption.
crospovidon, magnesiumstearat - filmovertræk: hypromellose, titandioxid, triacetin, indigocarmin, brilliant blue FCF. 
crospovidone, magnesium stearate - film-coating:hypromellose, titanium dioxide, triacetin, indigo carmine, brilliant blue FCF.
Tabel 1 Bivirkninger efter systemorganklasse og hyppighed Systemorganklasse 
Table 1 Adverse reactions by System Organ Class and frequency
Lesinurad er i høj grad proteinbundet og renal clearance er høj (i sammenligning med den typiske humane glomerulære filtrationsrate), hvilket indikerer, at aktiv udskillelse spiller en vigtig rolle ved renal udskillelse af lesinurad. 
Lesinurad is highly protein bound and renal clearance is high (as compared to typical human glomerular filtration rate), indicating that active secretion plays an important role in the renal excretion of lesinurad.
Udbruddet bør håndteres sideløbende på hensigtsmæssig vis for den enkelte patient. 
The gout flare should be managed concurrently as appropriate for the individual patient.
Lesinurad akkumuleres ikke efter gentagne doser. 
Lesinurad does not accumulate following multiple doses.
BLISTER IKKE-PERFORERET (10 TABLETTER) BLISTER PERFORERET ENKELTDOSIS KALENDERBLISTER (14 TABLETTER) 
BLISTER NON-PERFORATED (10 TABLETS) BLISTER PERFORATED UNIT DOSE CALENDAR BLISTER (14 TABLETS)
Lesinurad påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. 
Lesinurad has no or negligible influence on the ability to drive and use machines.
Eksisterende kardiovaskulær sygdom 
Pre-existing cardiovascular disease
** Inkluderer de foretrukne termer: nyresvigt, kronisk nyresvigt og akut nyresvigt. 
**Includes the preferred terms: renal failure, renal failure chronic and renal failure acute.
* Fotodermatit, fotosensibilitetsreaktion, allergisk dermatitis, pruritus og urticaria. 
*Photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria.
66 % af patienterne havde let eller moderat nedsat nyrefunktion. 
Sixty-six percent of patients had mild or moderate renal impairment.
Anden medicin kan også påvirke den måde, hvorpå Zurampic virker. 
Also some other medicines can affect the way Zurampic works.
Forholdet mellem atropisomer 1- og atropisomer 2-AUC(0-24) var 44:56, fordi atropisomer 1 gennemgår mere ekstensiv metabolisering end atropisomer 2, hvorfor atropisomer 1 har lavere plasmaeksponering end atropisomer 2. 
The ratio of atropisomer 1 to atropisomer 2 AUC(0-24) was 44:56 because atropisomer 1 undergoes more extensive metabolism than atropisomer 2, causing atropisomer 1 to have lower plasma exposure than atropisomer 2.
Behandlingen med Zurampic skal afbrydes, hvis serumkreatinin stiger til mere end to gange værdien før behandling eller i tilfælde af en absolut serumkreatinin > 4,0 mg/dl. 
Zurampic should be interrupted if serum creatinine is elevated to greater than 2 times the pre-treatment value or in case of an absolute serum creatinine value greater than 4.0 mg/dL.
På baggrund af in vitro-data kan lesinurad være en let CYP2B6-induktor, men denne interaktion er ikke undersøgt klinisk. 
Based on in vitro data, lesinurad may be a mild inducer of CYP2B6 but this interaction has not been studied clinically.
Gennemsnitlige plasma:blod-ratioer for lesinurad-AUC og -Cmax var ca. 1,8, hvilket indikerer, at radioaktiviteten for størstedelen blev indeholdt i plasma og ikke penetrerede eller fordeltes til de røde blodlegemer i udstrakt grad. 
Mean plasma-to-blood ratios of lesinurad AUC and Cmax were approximately 1.8, indicating that radioactivity was largely contained in the plasma space and did not penetrate or partition extensively into red blood cells.
Omtrent halvdelen af en oral dosis lesinurad elimineres via CYP2C9-metabolisme. 
Approximately half of an oral dose of lesinurad is cleared via CYP2C9 metabolism.
Zurampic er ikke undersøgt hos patienter med svært nedsat leverfunktion, og der kan derfor ikke gives dosisanbefalinger. 
Zurampic has not been studied in patients with severe hepatic impairment; therefore, dose recommendations cannot be given.
Patienter med tumorlysesyndrom eller Lesch-Nyhans syndrom. 
Patients with tumour lysis syndrome or Lesch-Nyhan syndrome.
Nyrefunktionen skal måles inden start med Zurampic og monitoreres regelmæssigt derefter, dvs. 4 gange om året, baseret på kliniske overvejelser, såsom baseline-nyrefunktion, hypovolæmi, samtidig sygdom eller anden samtidig medicin. 
Renal function should be evaluated prior to initiation of Zurampic and monitored periodically thereafter, e.g. 4 times per year, based on clinical considerations, such as baseline renal function, volume depletion, concurrent illness or concomitant medications.
Tabletovertræk hypromellose titandioxid triacetin 
Tablet coat hypromellose titanium dioxide triacetin
Det forventes, at andre moderate CYP2C9-hæmmere, såsom amiodaron, også påvirker farmakokinetikken for lesinurad i lignende grad. 
Other moderate CYP2C9 inhibitors, such as amiodarone, would also be expected to affect lesinurad pharmacokinetics to a similar degree.
ENTYDIG IDENTIFIKATOR - MENNESKELIGT LÆSBARE DATA <PC: {nummer} 
UNIQUE IDENTIFIER -HUMAN READABLE DATA
Plasmaproteinbindingen ændres ikke betydeligt hos patienter med nedsat nyre- eller leverfunktion. 
Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
Zurampic-behandlingen bør ikke startes igen, medmindre der er en anden forklaring på de abnorme serumkreatininværdier. 
Zurampic should not be restarted without another explanation for the serum creatinine abnormalities.
Du skal undgå at tage Zurampic under graviditet, og hvis du ammer. 
You should avoid taking Zurampic during pregnancy or if you are breast-feeding.
Hos patienter med tofi eller vedvarende symptomer er målet under 5 mg/dl (300 µmol/l). 
In patients with tophi or persistent symptoms, the target is less than 5 mg/dL (300 µmol/L).
Tabletkerne hypromellose mikrokrystallinsk cellulose lactosemonohydrat crospovidon type A magnesiumstearat 
Tablet core hypromellose microcrystalline cellulose lactose monohydrate crospovidone type A magnesium stearate
Erfaringen med meget ældre (≥75 år) er begrænset (se pkt. 
Experience in very elderly (≥75 years) is limited (see section 4.4).
Hvis dette sker, skal du blive ved med at tage Zurampic og tale med din læge eller apotekspersonalet. 
If this happens, keep taking Zurampic and talk to your doctor or pharmacist.
50 % af patienterne havde sUA ≥5,0 mg/dl ved baseline, hvilket var efter 3 ugers behandling med febuxostat alene. 
Fifty percent of patients had a baseline sUA ≥5.0 mg/dL, which was after 3 weeks of treatment with febuxostat alone.
Efter fortsat behandling i op til 24 måneder med Zurampic 200 mg i kombination med febuxostat steg andelen af forsøgspersoner, som oplevede fuldstændig resolution af mindst ét target-tophus, til 53 %. 
After continued treatment of up to 24 months on Zurampic 200 mg in combination with febuxostat, the proportion of subjects who experienced complete resolution of at least one target tophus increased to 53% of subjects.
Behandlingen bør afbrydes hos patienter, som melder om symptomer, der kan tyde på akut urinsyrenefropati, herunder flankesmerter, kvalme eller opkastning, og serumkreatinin skal straks måles. 
Treatment should be interrupted in patients who report symptoms that may indicate acute uric acid nephropathy including flank pain, nausea or vomiting, and measure serum creatinine promptly.
Hæmmere af mikrosomal epoxidhydrolase (mEH) (fx valproinsyre, valpromid) kan interferere med metaboliseringen af lesinurad. 
Inhibitors of microsomal Epoxide Hydrolase (mEH) (e.g. valproic acid, valpromide) may interfere with the metabolism of lesinurad.
Trafik- og arbejdssikkerhed Zurampic forventes ikke at påvirke din evne til at køre bil eller bruge værktøj eller maskiner. 
Driving and using machines Zurampic is not expected to affect you being able to drive a car or use any tools or machines.
I interaktionsstudier udført hos raske forsøgspersoner med Zurampic og CYP3A-substrater reducerede lesinurad plasmakoncentrationen af sildenafil og amlodipin. 
In interaction studies conducted in healthy subjects with Zurampic and CYP3A substrates, lesinurad reduced the plasma concentrations of sildenafil and amlodipine.
Kontinuerlig behandling med Zurampic mindsker hyppigheden af udbrud af urinsyregigt. 
Continuous treatment with Zurampic decreases the frequency of gout flares.
Alle studier var af 12 måneders varighed, og patienterne fik profylakse mod udbrud af urinsyregigt med colchicin eller NSAID i de første 5 måneder med lesinurad. 
All studies were of 12 months duration and patients received prophylaxis for gout flares with colchicine or NSAIDs during the first 5 months of lesinurad treatment.
Inden for 7 dage efter en enkelt dosis radioaktivt mærket lesinurad blev 63 % af den administrerede radioaktive dosis genfundet i urin og 32 % i fæces. 
Within 7 days following single dosing of radiolabelled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of administered radioactive dose was recovered in faeces.
Hvis du stopper med at tage din xanthinoxidasehæmmer, skal du også stoppe med at tage Zurampic. 
If you stop taking your xanthine oxidase inhibitor medicine, you must also stop taking Zurampic.
Derfor anbefales det, at patienterne monitoreres for nedsat effekt af CYP2B6-substrater (fx bupropion, efavirenz) ved administration sammen med Zurampic. 
Therefore, it is recommended that patients are monitored for reduced efficacy of CYP2B6 substrates (e.g. bupropion, efavirenz) when co-administered with Zurampic.
Der er ingen klinisk erfaring hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C). 
There is no clinical experience in patients with severe (Child-Pugh class C) hepatic impairment.
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Zurampic i alle undergrupper af den pædiatriske population ved behandling og forebyggelse af hyperurikæmi (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Zurampic in all subsets of the paediatric population for the treatment and prevention of hyperuricaemia (see section 4.2 for information on paediatric use).
I et interaktionsstudie udført hos raske forsøgspersoner, der fik multiple doser Zurampic 400 mg og en enkelt dosis warfarin (25 mg), medførte lesinurad et fald i eksponeringen for R-warfarin (den mindst aktive enantiomer) og havde ingen indvirkning på eksponeringen for S-warfarin (den mest aktive enantiomer). 
In an interaction study conducted in healthy subjects with multiple doses of Zurampic 400 mg and single dose warfarin (25 mg), lesinurad led to a decrease in exposure of R-warfarin (the less active enantiomer) and had no effect on the exposure of S-warfarin (the more active enantiomer).
Hjælpestof, som behandleren skal være opmærksom på: En tablet indeholder 52,92 mg lactose (som monohydrat). 
Excipient with known effect: Each tablet contains 52.92 mg of lactose (as monohydrate).
Den anbefalede minimaldosis af allopurinol er 300 mg, eller 200 mg til patienter med moderat nedsat nyrefunktion (kreatininclearance [CrCL] 30-59 ml/min). 
The recommended minimum dose of allopurinol is 300 mg, or 200 mg for patients with moderate renal impairment (creatinine clearance [CrCL] of 30-59 mL/min).
Tag ikke Zurampic: - hvis du er allergisk over for lesinurad eller et af de øvrige indholdsstoffer i Zurampic (angivet i punkt 6). 
Do not take Zurampic: - if you are allergic to lesinurador any of the other ingredients of this medicine (listed in section
Baseret på lesinurads virkningsmekanisme er det ikke nødvendigvis effektivt hos disse patienter (se pkt. 
Based on its mechanism of action, lesinurad may not be effective in these patients (see section 5.1).
Det skal du vide, før du begynder at tage Zurampic 
What you need to know before you take Zurampic
Den anbefalede dosis er 1 tablet på 200 mg én gang dagligt om morgenen. 
The recommended dose is 1 tablet of 200 mg once a day in the morning.
Derfor anbefales det, at Zurampic anvendes med forsigtighed til patienter, der tager moderate CYP2C9-hæmmere. 
Therefore, it is recommended that Zurampic should be used with caution in patients taking moderate inhibitors of CYP2C9.
Den populationsfarmakokinetiske analyse af kliniske data hos patienter med urinsyregigt behandlet i op til 12 måneder estimerede stigning i lesinuradeksponeringen på ca. 12 %, 31 % og 65 % hos patienter med henholdsvis let, moderat og svært nedsat nyrefunktion, sammenlignet med patienter med normal nyrefunktion. 
The population pharmacokinetic analysis of clinical data in gout patients treated for up to 12 months estimated increases in lesinurad exposure of approximately 12%, 31% and 65% in patients with mild, moderate, and severe renal impairment, respectively, compared with patients with normal renal function.
Hvis behandlingen med xanthinoxidasehæmmeren afbrydes, skal behandlingen med Zurampic også afbrydes. 
If treatment with the xanthine oxidase inhibitor is interrupted, Zurampic dosing must also be interrupted.
Hvis noget af ovenstående gælder for dig (eller hvis du er i tvivl), skal du tale med lægen eller apotekspersonalet, inden du tager Zurampic. 
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Zurampic.
Gennnemsnitlig sUA-reduktion efter administration af Zurampic 200 mg alene var ca. 46 % og 26 % henholdsvis 6 timer og 24 timer efter dosering. 
Mean sUA reductions following Zurampic 200 mg administration alone were approximately 46% and 26% at 6 hours and 24 hours post-dose, respectively.
Yderligere monitorering af lipider og blodtryk anbefales hos patienter, som tager lipidsænkende lægemidler, der er sensitive CYP3A-substrater (såsom lovastatin eller simvastatin) eller antihypertensiv medicin (såsom amlodipin, felodipin eller nisoldipin), da deres effekt kan blive nedsat (se pkt. 
Additional monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate lipid lowering medicines (such as lovastatin or simvastatin) or antihypertensive medicines (such as amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5).
I de kliniske studier var de fleste bivirkninger lette eller moderate i intensitet og forsvandt ved fortsat Zurampicbehandling. 
In clinical trials, most adverse reactions were mild or moderate in intensity and resolved while continuing Zurampic therapy.
Zurampic indeholder: 
How Zurampic works:
Manglen på en observeret interaktion kunne skyldes kombinationen af CYP2C9induktion og OATP1B1- og 1B3-hæmning. 
The lack of an observed interaction could be due to the combination of the induction of CYP2C9 and inhibition of OATP1B1 and 1B3.
Urinsyregigt er en type leddegigt, der skyldes en ophobning af uratkrystaller omkring leddene. 
Gout is a type of arthritis caused by an accumulation of urate crystals around the joints.
Vent og tag din næste dosis af Zurampic med din næste morgendosis af allopurinol eller febuxostat. 
Wait and take your next dose of Zurampic with your next morning dose of allopurinol or febuxostat.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen eller blisterfolien efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton or blister foil after “EXP”.
Fluconazol, som er en moderat CYP2C9-hæmmer, øgede lesinurad-AUC (56 %) og -Cmax (38 %) samt den mængde lesinurad, der blev udskilt uomdannet i urinen. 
Fluconazole, a moderate CYP2C9 inhibitor, increased lesinurad AUC (56%) and Cmax (38%), as well as the amount of lesinurad excreted unchanged in urine.
Ikke almindelig - kan forekomme hos op til 1 ud af 100 personer - nyresten, - dehydrering (tab af for meget væske fra kroppen). 
Uncommon - may affect up to 1 in 100 people - kidney stones, - dehydration (loss of too much fluid from your body).
På baggrund af interaktionsstudier hos raske forsøgspersoner eller patienter med urinsyregigt har Zurampic ikke klinisk signifikante interaktioner med NSAID (naproxen og indomethacin), colchicin, repaglinid, tolbutamid, febuxostat eller allopurinol. 
Based on interaction studies in healthy subjects or gout patients, Zurampic does not have clinically significant interactions with NSAIDs (naproxen and indomethacin), colchicine, repaglinide, tolbutamide, febuxostat or allopurinol.
Der er rapporteret sjældne tilfælde af overfølsomhed (fotodermatit, fotosensibilitetsreaktion, allergisk dermatit, pruritus og urticaria) med lesinurad i det kliniske program. 
Rare cases of hypersensitivity (photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria) have been reported with lesinurad during the clinical programme.
Fedtindholdet i måltidet havde tilsyneladende ingen indvirkning på lesinurads farmakokinetik. 
There was no apparent influence of the fat content in the meal on the pharmacokinetics of lesinurad.
Zurampic 200 mg tabletter fås i klare blisterpakninger i pakningsstørrelser på 10, 28, 30 eller 98 ikkeperforerede blisterpakninger og 100 x 1 perforerede enkeltdosisblisterpakninger. 
Zurampic 200 mg tablets are available in clear blisters in pack sizes of 10, 28, 30 or 98 non-perforated blisters and 100 x 1 perforated unit dose blisters.
Det skal tages i betragtning, at der er mulighed for nedsat effekt af samtidige lægemidler, der er CYP3A-substrater, og deres effekt (fx blodtryk og kolesterolniveau) skal monitoreres (se pkt. 
The possibility of reduced efficacy of concomitant medicinal products that are CYP3A substrates should be considered and their efficacy (e.g. blood pressure and cholesterol levels) should be monitored (see section 4.4).
Salicylater i doser over 325 mg pr. dag kan reducere lesinurads serumurinsyresænkende aktivitet og bør ikke administreres sammen med Zurampic. 
Salicylates at doses higher than 325 mg per day may decrease the serum uric acid lowering activity of lesinurad and should not be co-administered with Zurampic.
Det primære effektendepunkt i både CLEAR1 og CLEAR2 var andelen af patienter, der nåede et målniveau for serumurinsyre på under 6 mg/dl ved Måned 6. 
The primary efficacy endpoint in both CLEAR1 and CLEAR2 was the proportion of patients achieving a serum uric acid target level of less than 6 mg/dL by Month 6.
Almindelig - kan forekomme hos op til 1 ud af 10 personer - influenza, - hovedpine, - forhøjet indhold af kreatinin i blodet - kan ses i prøver, - halsbrand (sure opstød). 
Common - may affect up to 1 in 10 people - flu (influenza), - headache, - increase in the amount of creatinine in your blood -shown in tests, - heartburn(acid reflux).
Den anbefalede dosis af Zurampic er 200 mg én gang dagligt om morgenen. 
The recommended dose of Zurampic is 200 mg once daily in the morning.
Zurampic medførte en let nedsat eksponering for oxypurinol (et URAT1-substrat), hovedmetabolitten af allopurinol; dog var den urinsyrenedsættende virkning af kombinationen med allopurinol signifikant større end for de enkelte stoffer alene. 
Zurampic slightly decreased exposure of oxypurinol (a URAT1 substrate), the major metabolite of allopurinol; however, the uric acid-lowering effect of the combination with allopurinol was significantly greater than for either substance alone.
På grund af utilstrækkelige data frarådes Zurampic til patienter med ustabil angina, New York Heart Association (NYHA)-klasse III eller IV hjertesvigt, ukontrolleret hypertension, med en nylig episode af myokardieinfarkt eller apopleksi eller med dyb venetrombose inden for de foregående 12 måneder. 
Zurampic is not recommended in patients with unstable angina, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled hypertension or with a recent event of myocardial infarction, stroke, or deep venous thrombosis within the last 12 months, due to insufficient data.
Zurampic må aldrig tages uden en xanthinoxidasehæmmer. 
Zurampic must never be taken without a ‘xanthine oxidase inhibitor' medicine.
Patienterne skal informeres om, at manglende efterlevelse af disse instruktioner kan øge risikoen for nyrepåvirkninger (se pkt. 
Patients should be informed that failure to follow these instructions may increase the risk of renal events (see section 4.4).
Zurampic indeholder det aktive stof lesinurad og anvendes til behandling af urinsyregigt hos voksne patienter, idet det nedsætter indholdet af urinsyre i blodet. 
Zurampic contains the active ingredient lesinurad and is used to treat gout in adult patients by lowering the levels of uric acid in the blood.
Der er begrænset erfaring med Zurampic hos patienter med en estimeret CrCL (eCrCL) under 45 ml/min; Zurampic skal derfor anvendes med forsigtighed til patienter med CrCL fra 30 ml/min til < 45 ml/min. 
Experience with Zurampic in patients with an estimated CrCL (eCrCL) less than 45 mL/min is limited; therefore, Zurampic should be used with caution in patients with a CrCL from 30 mL/min to less than 45 mL/min.
Lesinurad hæmmer også OAT4, en urinsyretransportør, der er involveret i diuretikainduceret hyperurikæmi. 
Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced hyperuricaemia.
Sekundær hyperurikæmi 
Secondary hyperuricaemia
Dette skyldes det nedsatte serumurinsyreniveau, som medfører mobilisering af urat fra vævsdepoter. 
This is due to reduction in serum uric acid levels resulting in mobilisation of urate from tissue deposits.
Efter en enkelt dosis lesinurad på 200 mg i forbindelse med fødeindtagelse var den geometriske middelværdi af Cmax og AUC henholdsvis 6 μg/ml og 29 μg/t/ml. 
In the fed state, after a single dose of lesinurad 200 mg, geometric mean lesinurad Cmax and AUC were 6 μg/mL and 29 μg/hr/mL, respectively.
Zurampic må ikke påbegyndes hos nyretransplanterede patienter. 
Zurampic should not be initiated in kidney transplant recipients.
Derudover inducerer lesinurad CYP2B6 og CYP3A via CAR/PXR in vitro. 
In addition, lesinurad is an in vitro inducer of CYP2B6 and CYP3A via CAR/PXR.
Det tilstræbte serumurinsyreniveau er under 6 mg/dl (360 µmol/l). 
The target serum uric acid level is less than 6 mg/dL (360 µmol/L).
Der kan allerede udføres test af serumurinsyre 4 uger efter behandlingsstart med Zurampic. 
Testing for the target serum uric acid level may be performed as early as 4 weeks after initiating Zurampic treatment.
Pakningsstørrelse a 100 x 1 filmovertrukket tablet i perforerede enkeltdosisblistere. 
Pack size of 100 x 1 film-coated tablet in perforated unit dose blisters.
De hyppigst indberettede bivirkninger under behandling med Zurampic 200 mg er influenza, gastroøsofageal reflukssygdom, hovedpine og forhøjet kreatinin i blodet. 
The most commonly reported adverse reactions during treatment with Zurampic 200 mg are influenza, gastro-oesophageal reflux disease, headache and blood creatinine increased.
Behandlingsgruppe: --o-- Placebo + allopurinol, 
--o-- Placebo + Allopurinol,
Gennemsnitlig (SE) urinsyre i serum (mg/dl) 
Mean (SE) Serum Uric Acid (mg/dL)
De alvorlige bivirkninger nyresvigt, nedsat nyrefunktion og nyresten forekom med hyppigheden ”ikke almindelig” (mindre end 1 tilfælde pr. 100 patienter) (se Tabel 1). 
The serious adverse reactions renal failure, renal impairment and nephrolithiasis have occurred uncommonly (less than 1 case per 100 patients) (see Table 1).
HMG-CoA-reduktasehæmmere, der er sensitive CYP3A-substrater, kan interagere med lesinurad. 
HMG-CoA reductase inhibitors that are sensitive CYP3A substrates may interact with lesinurad.